# Veloxis de Novo Kidney Transplant ECSWD

> **NCT03828682** · PHASE4 · UNKNOWN · sponsor: **Simon Tremblay, PharmD, PhD** · enrollment: 60 (estimated)

## Conditions studied

- Kidney Transplantation
- Immunosuppression

## Interventions

- **DRUG:** Tacrolimus Extended Release Oral Tablet [Envarsus]
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Mycophenolic Acid Oral Product
- **DRUG:** Tacrolimus
- **DRUG:** Methylprednisolone
- **DRUG:** Prednisone
- **DRUG:** Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]

## Key facts

- **NCT ID:** NCT03828682
- **Lead sponsor:** Simon Tremblay, PharmD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-21
- **Primary completion:** 2021-07-31
- **Final completion:** 2022-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03828682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03828682, "Veloxis de Novo Kidney Transplant ECSWD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03828682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*